Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 14, 2017
CEL-SCI CORPORATION
-----------------------------
(Exact name of Registrant as specified in its charter)
Colorado 01-11889 84-0916344
--------------------------- ------------------ ----------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
-------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-------------------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On August 14, 2017 the Company announced it has received a letter from the
U.S. Food and Drug Administration stating that the clinical hold that had been
imposed on the Company's Phase 3 cancer study with Multikine has been removed
and that all clinical trial activities under this Investigational New Drug
application (IND) may resume.
On August 14, 2017 the Company issued a press release, filed as Exhibit 99,
announcing the release of the clinical hold.
Item 9.01 Financial Statements and Exhibits
Exhibit Description
99 Press Release dated August 14, 2017
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 14, 2017
CEL-SCI CORPORATION
By: /s/ Patricia B. Prichep
--------------------------------------
Patricia B. Prichep
Senior Vice President of Operation
